ScreenerHero

CDNA CareDx, Inc.

NAS · US · Healthcare · Diagnostics & Research · caredx.com
69.85USD+4.02%Mkt Cap: 3.61B $P/E: 33.58

CareDx, Inc. provides solutions for improving outcomes for transplant patients and advancing organ health in the United States and internationally. The company provides AlloSure Kidney, a donor-derived cell-free DNA (dd-…

Industry Peers

Diagnostics & Research
Screen all
TMO
Thermo Fisher Scientific Inc.
$250.23BUSDP/E 36.4
DHR
Danaher Corporation
$155.51BUSDP/E 39.4
NTRA
Natera, Inc.
$61.35BUSD
LONN
Lonza Group AG
$45.82BUSDP/E 38.1
A
Agilent Technologies, Inc.
$48.29BUSDP/E 33.8
ILMN
Illumina, Inc.
$44.35BUSDP/E 54.8
IQV
IQVIA Holdings Inc.
$43.80BUSDP/E 33.1
WAT
Waters Corporation
$43.21BUSDP/E 111.4
IDXX
IDEXX Laboratories, Inc.
$41.58BUSDP/E 37.0
MTD
Mettler-Toledo International Inc.
$30.89BUSDP/E 34.7
DGX
Quest Diagnostics Incorporated
$25.63BUSDP/E 24.7
GH
Guardant Health, Inc.
$25.12BUSD
LH
Labcorp Holdings Inc.
$25.03BUSDP/E 25.5
RVTY
Revvity, Inc.
$17.56BUSDP/E 75.3
MEDP
Medpace Holdings, Inc.
$17.32BUSDP/E 36.4
CRL
Charles River Laboratories International, Inc.
$14.84BUSD
ERF
Eurofins Scientific SE
$14.05BUSDP/E 26.2
ICLR
ICON Public Limited Company
$12.99BUSDP/E 177.2
BIM
bioMérieux S.A.
$10.02BUSDP/E 20.0
QGEN
Qiagen N.V.
$9.46BUSDP/E 23.2

Key Statistics

Company
Market Cap3.61B USD
Enterprise Value3.12B USD
Revenue (TTM)458.09M USD
Gross Profit256.57M USD
Net Income (TTM)-21.35M USD
Revenue/Share8.89 USD
Last Price69.85 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees761
CountryUS
SectorHealthcare
IndustryDiagnostics & Research
ISIN—
Valuation
P/E (Trailing)33.58
P/E (Forward)52.05
PEG—
EV/EBITDA250.91
EV/Revenue6.81
P/S7.58
P/B8.12
EPS (TTM)2.08
EPS (Forward)1.29
52W Range
13.9598% of range70.75
52W High70.75 USD
52W Low13.95 USD
Profitability
Gross Margin67.55%
Oper. Margin0.19%
EBITDA Margin2.71%
Profit Margin-5.62%
ROE-7.05%
ROA-5.17%
Growth
Revenue Growth52.20%
Earnings Growth—
Cash Flow & Leverage
Operating CF42.03M USD
CapEx (TTM)6.59M USD
FCF Margin24.48%
FCF Yield3.10%
Net Debt-354.39M USD
Net Debt/EBITDA-28.50
Balance Sheet
Debt/Equity0.09
Current Ratio4.58
Quick Ratio4.36
Book Value/Sh8.27 USD
Cash/Share7.22 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.6 (Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)58.83 USD
Upside (mean)-15.8%
Target Range46.00 USD – 74.00 USD
46.00-15.8% to mean74.00
# Analysts6
Ownership
Shares Out.51.73M
Float49.45M
Insiders3.13%
Institutions103.47%
Short Interest
Short Ratio5.6d
Short % Float12.40%
Short % Out.12.17%
Shares Short6.30M
Short (prev mo.)5.79M
Technical
SMA 5050.25 (+39.0%)
SMA 20028.76 (+142.9%)
Beta2.43
S&P 52W Chg14.58%
Avg Vol (30d)1.27M
Avg Vol (10d)1.66M
Technical Indicators
RSI (14)84.5
MACD5.6845
MACD Signal4.7585
MACD Hist.+0.9260
BB Upper71.33 USD
BB Middle57.36 USD
BB Lower43.40 USD
BB Width48.70%
ATR (14)3.051 USD
Vol Ratio (20d)1.23x